Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Vaccination with filamentous bacteriophages targeting DEC-205 induces DC maturation and potent anti-tumor T-cell responses in the absence of adjuvants.

Sartorius R, Bettua C, D'Apice L, Caivano A, Trovato M, Russo D, Zanoni I, Granucci F, Mascolo D, Barba P, Del Pozzo G, De Berardinis P.

Eur J Immunol. 2011 Sep;41(9):2573-84. doi: 10.1002/eji.201141526. Epub 2011 Aug 18.

2.

Targeting the antigen encoded by adenoviral vectors to the DEC205 receptor modulates the cellular and humoral immune response.

Tenbusch M, Nchinda G, Storcksdieck genannt Bonsmann M, Temchura V, Überla K.

Int Immunol. 2013 Apr;25(4):247-58. doi: 10.1093/intimm/dxs112. Epub 2012 Nov 26.

3.

Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.

Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, Schuler-Thurner B, Schuler G, Schaft N, Dörrie J.

Blood. 2010 Sep 30;116(13):2277-85. doi: 10.1182/blood-2010-02-268425. Epub 2010 Jun 21.

4.

Exploring the vaccine potential of Dec-205 targeting in Mycobacterium tuberculosis infection in mice.

Stylianou E, Pepponi I, van Dolleweerd CJ, Paul MJ, Ma JK, Reljic R.

Vaccine. 2011 Mar 9;29(12):2279-86. doi: 10.1016/j.vaccine.2011.01.030. Epub 2011 Jan 25.

PMID:
21272603
5.

Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC-205 single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response.

Sartorius R, D'Apice L, Trovato M, Cuccaro F, Costa V, De Leo MG, Marzullo VM, Biondo C, D'Auria S, De Matteis MA, Ciccodicola A, De Berardinis P.

EMBO Mol Med. 2015 Apr 17;7(7):973-88. doi: 10.15252/emmm.201404525.

6.

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.

Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F.

Cancer Immunol Immunother. 2004 Nov;53(11):963-77. Epub 2004 May 14.

PMID:
15146294
7.

Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule.

Johnson TS, Mahnke K, Storn V, Schönfeld K, Ring S, Nettelbeck DM, Haisma HJ, Le Gall F, Kontermann RE, Enk AH.

Clin Cancer Res. 2008 Dec 15;14(24):8169-77. doi: 10.1158/1078-0432.CCR-08-1474.

9.

Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.

Grossmann C, Tenbusch M, Nchinda G, Temchura V, Nabi G, Stone GW, Kornbluth RS, Uberla K.

BMC Immunol. 2009 Aug 3;10:43. doi: 10.1186/1471-2172-10-43.

10.

A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo.

Soares H, Waechter H, Glaichenhaus N, Mougneau E, Yagita H, Mizenina O, Dudziak D, Nussenzweig MC, Steinman RM.

J Exp Med. 2007 May 14;204(5):1095-106. Epub 2007 Apr 16.

11.

Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.

Worgall S, Busch A, Rivara M, Bonnyay D, Leopold PL, Merritt R, Hackett NR, Rovelink PW, Bruder JT, Wickham TJ, Kovesdi I, Crystal RG.

J Virol. 2004 Mar;78(5):2572-80.

12.

Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.

Singh SK, Stephani J, Schaefer M, Kalay H, García-Vallejo JJ, den Haan J, Saeland E, Sparwasser T, van Kooyk Y.

Mol Immunol. 2009 Dec;47(2-3):164-74. doi: 10.1016/j.molimm.2009.09.026. Epub 2009 Oct 8.

PMID:
19818504
13.
14.

In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination.

Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM.

J Exp Med. 2004 Mar 15;199(6):815-24.

15.
16.

Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.

Cruz LJ, Rosalia RA, Kleinovink JW, Rueda F, Löwik CW, Ossendorp F.

J Control Release. 2014 Oct 28;192:209-18. doi: 10.1016/j.jconrel.2014.07.040. Epub 2014 Jul 25.

PMID:
25068703
17.

In vivo targeting of human DC-SIGN drastically enhances CD8⁺ T-cell-mediated protective immunity.

Hesse C, Ginter W, Förg T, Mayer CT, Baru AM, Arnold-Schrauf C, Unger WW, Kalay H, van Kooyk Y, Berod L, Sparwasser T.

Eur J Immunol. 2013 Oct;43(10):2543-53. doi: 10.1002/eji.201343429. Epub 2013 Jul 22.

18.

Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.

Kalady MF, Onaitis MW, Emani S, Abdel-Wahab Z, Tyler DS, Pruitt SK.

J Surg Res. 2004 Jan;116(1):24-31.

PMID:
14732346
19.

Novel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant.

Wan T, Zhou X, Chen G, An H, Chen T, Zhang W, Liu S, Jiang Y, Yang F, Wu Y, Cao X.

Blood. 2004 Mar 1;103(5):1747-54. Epub 2003 Oct 30.

20.

Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8 alpha+ dendritic cells.

Tagliani E, Guermonprez P, Sepúlveda J, López-Bravo M, Ardavín C, Amigorena S, Benvenuti F, Burrone OR.

J Immunol. 2008 Mar 1;180(5):3201-9.

Items per page

Supplemental Content

Write to the Help Desk